Following the release of the 1H FY25 results, Catapult’s stock price rose to approximately AUD $3.38, reflecting the market’s ...
Virologist injects herself with novel, pre-operative cancer treatment, reducing tumour size in just a few weeks.
Xero's half year report showed its ability to increase prices in Australia, but hinted at a more difficult competitive situation in the USA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback